Microfluidic Market Emerging Growth By Top Players Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc

Major factors influencing growth of the microfluidic market is rising demand for point-of-care (POC) testing and advancements in microfluidic technology to reduce cost of sample analysis and enabling higher efficiency. Moreover, increasing demand for home healthcare to address growing prevalence of diabetes is supporting to growth of the microfluidic market. For instance, in 2017 researchers at the Ewha Womens University developed an endocrine system on chip, based on microfluidic perfused 3D cell-culture chip which detect the drugs for the treatment of diabetes by measuring insulin release over time.

Request Sample Copy Of This Report: www.coherentmarketinsights.com/insight/request-sample/1086

According to the statistics published by International Diabetes Federation (IDF), the global prevalence of diabetes is around 424.9 million in 2017, which is expected to increase to 628.6 million in 2045. In addition, increasing innovation in microfluidics technology is further expected to bolster growth of the market. Researchers at the Brigham Young University, in April 2017, developed first 3D-print viable microfluidic device which has size less than 100 micrometers and employed to use in molecular biology, proteomics and cell biology diagnostic technologies.

Moreover technology advancement in microfluidic saves the time, eliminate the need of expensive laboratory robots and reduce the risk of sample loss and contamination. For instance, in February 2017, researchers at the Stanford University School of Medicine have developed a relatively cheap and reusable diagnostic lab-on-a-chip for medical diagnostic application, which is expected to enhance the diagnostic capabilities and would be a highly feasible option in emerging economies.

Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1086

Key players in the microfluidic market are emphasizing on introducing innovative solutions based on microfluidic technology for a wide range of applications. For instance, in November 2017, Dolomite Bio introduced Nadia- a single-cell platform for single-cell RNA sequencing. Nadia is droplet microfluidic based instrument that can generate 6,000 single-cell libraries per sample in just 15 minutes. It also aids researchers to run multiple samples parallelly. Dolomite Bio combines the microfluidic technology with automated temperature control and cell/bead agitation in single instrument that delivers highly precise and reliable results.

OPKO Health, Inc., in November 2017 submitted the Premarket Approval (PMA) application to US FDA for Claros 1 immunoassay analyzer. Claros 1 immunoassay analyzer is a diagnostic instrument system, which uses microfluidics technology to provide quick and quantitative blood test result in just 10 minutes by eliminating the need of external reagent, instrument calibration and maintenance.

Some of the major players operating in the microfluidic market are Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation, Danaher Corporation, PerkinElmer Inc., Siemens Healthcare GmbH, and Micronit Microfluidic BV

Make an inquiry for purchasing this report @ www.coherentmarketinsights.com/insight/buy-now/1086

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.